Clinical Trials Register

Trials with a EudraCT protocol (16)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

16 result(s) found for: Urethral Carcinoma. Displaying page 1 of 1.

EudraCT Number: 2013-002417-35

Sponsor Protocol Number: NUCOGI-VINGEM

Start Date*: 2013-09-10

Sponsor Name:Department of Oncology, Karolinska University Hospital

Full Title: A multicenter, randomized phase II trial of vinflunine/gemcitabine versus carboplatin /gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based...

Medical condition: Locally advanced or Metastatic urothelial carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.1	100000004864	10046721	Urothelial carcinoma bladder stage III	LLT
	18.1	100000004864	10046723	Urothelial carcinoma ureter	LLT
	18.1	100000004864	10046714	Urothelial carcinoma bladder	LLT
	18.1	100000004864	10046722	Urothelial carcinoma bladder stage IV	LLT
	18.1	100000004864	10046725	Urothelial carcinoma ureter metastatic	LLT
	18.1	100000004864	10046730	Urothelial carcinoma urethra metastatic	LLT
	18.1	100000004864	10046728	Urothelial carcinoma urethra	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Completed) DK (Completed) FI (Completed)

Trial results: View results

EudraCT Number: 2022-000514-33

Sponsor Protocol Number: OZBS62.20366

Start Date*: 2022-10-10

Sponsor Name:Erasmus MC

Full Title: CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT study

Medical condition: Urothelial cancer of the bladder, upper urinary tract or urethra.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10046714	Urothelial carcinoma bladder	LLT
	20.0	100000004864	10046723	Urothelial carcinoma ureter	LLT
	20.0	100000004864	10046728	Urothelial carcinoma urethra	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-001527-39

Sponsor Protocol Number: SGN22E-002

Start Date*: 2021-02-16

Sponsor Name:Seagen Inc.

Full Title: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Medical condition: Urothelial cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10046714	Urothelial carcinoma bladder	LLT
	20.0	100000004864	10046723	Urothelial carcinoma ureter	LLT
	20.0	100000004864	10046728	Urothelial carcinoma urethra	LLT
	21.1	100000004864	10077840	Urothelial cancer of renal pelvis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) IT (Completed)

Trial results: (No results available)

EudraCT Number: 2010-020397-42	Sponsor Protocol Number: UROL2008/5	Start Date*: 2010-12-22
Sponsor Name:VUmc Dept Urology
Full Title: The efficacy of an antigenic marker lesion for the therapeutic effect in patients with multiple, Ta/T1, G1/G2, non-muscle invasive bladder cancer (NMIBC) treated with TUR followed by IL-2 instillation
Medical condition: Multiple, Ta / T1, G1 / G2, non-muscle invasive bladder carcinoma
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2010-022653-41

Sponsor Protocol Number: INT52/10

Start Date*: 2010-11-25

Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI

Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder.

Medical condition: Muscle-invasive transitional cell carcinoma of the bladder at clinical stage T>/=2N0.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10005084		LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2014-003625-17

Sponsor Protocol Number: CA209-275

Start Date*: 2015-01-27

Sponsor Name:Bristol-Myers Squibb International Corporation

Full Title: A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agen...

Medical condition: metastatic or unresectable urothelial cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046723	Urothelial carcinoma ureter	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046714	Urothelial carcinoma bladder	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10064467	Urothelial carcinoma	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10005003	Bladder cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046728	Urothelial carcinoma urethra	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Ongoing) BE (Completed) SE (Completed) CZ (Completed) FI (Completed) PL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2018-001167-23

Sponsor Protocol Number: IMMU-132-06

Start Date*: 2019-03-20

Sponsor Name:Immunomedics, Inc.

Full Title: A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Medical condition: Histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract predominant

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10077840	Urothelial cancer of renal pelvis	LLT
	20.0	100000004864	10046714	Urothelial carcinoma bladder	LLT
	20.0	100000004864	10046723	Urothelial carcinoma ureter	LLT
	20.0	100000004864	10046728	Urothelial carcinoma urethra	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2017-003479-78

Sponsor Protocol Number: SGN22E-001

Start Date*: 2018-08-29

Sponsor Name:Seattle Genetics Inc.

Full Title: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoin...

Medical condition: Patients with locally advanced or metastatic urothelial cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10046714	Urothelial carcinoma bladder	LLT
	20.0	100000004864	10046723	Urothelial carcinoma ureter	LLT
	20.0	100000004864	10046728	Urothelial carcinoma urethra	LLT
	20.0	100000004864	10064467	Urothelial carcinoma	LLT
	20.0	100000004864	10077056	Urothelial carcinoma recurrent	LLT
	21.1	100000004864	10077840	Urothelial cancer of renal pelvis	LLT
	21.0	100000004864	10046715	Urothelial carcinoma bladder recurrent	LLT
	21.0	100000004864	10046721	Urothelial carcinoma bladder stage III	LLT
	21.0	100000004864	10046722	Urothelial carcinoma bladder stage IV	LLT
	21.0	100000004864	10046725	Urothelial carcinoma ureter metastatic	LLT
	21.0	100000004864	10046726	Urothelial carcinoma ureter recurrent	LLT
	21.0	100000004864	10046730	Urothelial carcinoma urethra metastatic	LLT
	21.0	100000004864	10046731	Urothelial carcinoma urethra recurrent	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Completed) NL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2017-000580-32

Sponsor Protocol Number: ARCADIA

Start Date*: 2019-03-20

Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"

Full Title: Cabozantinib plus Ddurvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm pro...

Medical condition: Patients with metastatic urothelial carcinoma who have relapsed after =1 chemotherapy regimen

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10046714	Urothelial carcinoma bladder	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2011-001841-34

Sponsor Protocol Number: PLUTO2011

Start Date*: 2012-01-12

Sponsor Name:NHS Greater Glasgow Health Board [...]

Full Title: A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium.

Medical condition: Relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10044426	Transitional cell carcinoma urethra	LLT
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10044420	Transitional cell carcinoma of the bladder stage unspecified	LLT
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10044407	Transitional cell cancer of the renal pelvis and ureter	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2021-001443-27

Sponsor Protocol Number: CA209-6E8,CNN-BC

Start Date*: 2021-11-02

Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE

Full Title: Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer. (CA209-6E8, C...

Medical condition: Patients with non-metastatic muscle invasive bladder cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066753	Bladder transitional cell carcinoma stage II	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2016-000049-30	Sponsor Protocol Number: RITE-2	Start Date*: 2017-07-26
Sponsor Name:Medical Enterprises Europe B.V
Full Title: A multicenter, single-arm study evaluating the efficacy of Synergo radiofrequency-induced thermochemotherapy effect (RITE) with Mitomycin C( Synergo + MMC) in non-muscle invasive bladder cancer (NM...
Medical condition: Non-Muscle-Invasive Bladder Cancer
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2013-003898-98

Sponsor Protocol Number: PDD_vs_WL-TURB_in_pazienti_con_NMIB

Start Date*: 2013-11-28

Sponsor Name:Ospedale San Raffaele

Full Title: COMPARISON OF WHITE LIGHT TUR VS PHOTODYNAMIC DIAGNOSIS (PDD)- GUIDED TUR AS ASSESSED BY SECOND LOOK TUR FOR THE TREATMENT OF HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC)

Medical condition: high grade non muscle invasive bladder cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10005003	Bladder cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2017-002323-25

Sponsor Protocol Number: AA1720

Start Date*: 2017-09-22

Sponsor Name:Center for cancer immune therapy

Full Title: Adoptive cell therapy across cancer diagnoses

Medical condition: Patients with metastatic solid cancers in stages III or IV regardless of diagnosis.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055099	Ocular cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055100	Otic cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055108	Thymic cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10050017	Lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059514	Small cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055104	Pharyngeal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055105	Sinus cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055096	Anal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10053548	Gastrointestinal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055097	Rectal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055114	Colon cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10052358	Colorectal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055098	Oral cavity cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055109	Tongue cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055102	Oesophageal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10050018	Renal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046394	Ureteric cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046433	Urethral cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055115	Skin cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055101	Bone cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055095	Adrenal gland cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055106	Pituitary cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055107	Thyroid cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055113	Breast cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055111	Biliary cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066879	Gallbladder cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055110	Hepatic cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055094	Cervix cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014734	Endometrial cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016182	Fallopian tube cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033158	Ovarian epithelial cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046887	Vaginal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10047742	Vulval cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036909	Prostate cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055103	Testicular cancer metastatic	PT
	20.0	100000016906	10033605	Pancreatic cancer metastatic	LLT
	20.0	100000016840	10023183	Jejunum cancer metastatic	LLT
	20.0	100000016840	10013816	Duodenal cancer metastatic	LLT
	20.0	100000016840	10023167	Jejunal cancer metastatic	LLT
	20.0	100000017543	10038498	Renal pelvis and ureter transitional cell cancer metastatic	LLT
	20.0	100000017543	10038509	Renal pelvis and ureteric cancer metastatic transitional cell	LLT
	20.0	100000017725	10046377	Ureter cancer metastatic	LLT
	20.0	100000017773	10046420	Urethra cancer metastatic	LLT
	20.0	100000021146	10036947	Prostatic cancer metastatic	LLT
	20.0	100000016931	10062478	Esophageal cancer metastatic	LLT
	20.0	100000143841	10063107	Tubular breast cancer metastatic	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10068694	Testicular germ cell cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10068971	Germ cell cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10069728	Rectosigmoid cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10069730	Large cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070902	Laryngeal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071540	Head and neck cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10072792	Tonsil cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10079104	Nasopharyngeal cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: View results

EudraCT Number: 2019-001310-42

Sponsor Protocol Number: BL.13

Start Date*: 2019-10-15

Sponsor Name:Canadian Cancer Trials Group (CCTG)

Full Title: A randomized phase II trial assessing trimodality therapy with or without adjuvant Durvalumab (MEDI4736) to treat patients with muscle-invasive bladder cáncer

Medical condition: Muscle-invasive bladder cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066753	Bladder transitional cell carcinoma stage II	PT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066754	Bladder transitional cell carcinoma stage III	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2012-000142-35

Sponsor Protocol Number: UC-0160/1105

Start Date*: 2014-05-19

Sponsor Name:UNICANCER

Full Title: A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-na...

Medical condition: metastatic hormone-naïve prostate cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036909	Prostate cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: FR (Completed) ES (Ongoing) IE (Completed) BE (Completed) IT (Completed) DE (Completed) RO (Completed) GR (Ongoing) PT (Completed)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Urethral Carcinoma